Association of G/A Polymorphism, rs266882, in AREI Region of the Prostate-Specific Antigen Gene with Prostate Cancer Risk and Clinicopathological Features

Urology Journal

Volumn 9, Issue 4, 2012, Pages 691-699

  Samzadeh, Mohammad ^a   Hasanzad, Mandana ^b   Jamaldini, Seyed Hamid ^c   Haghdoost, Ali Akbar ^d   Afshari, Mahdi ^d   Ziaee, Seyed Amir Mohsen ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benign prostatic hyperplasia; Genetics; Polymorphism; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; GENE FREQUENCY; GENETICS; GENOTYPE; HUMAN; IRAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; IRAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84876439303     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371-490.
2. Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun. 2000;276:125-33.
3. Xu J, Meyers DA, Sterling DA, et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostatespecific antigen genes. Cancer Epidemiol Biomarkers Prev. 2002;11:664-9.
4. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004;93:233-41.
5. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem. 1996;271:7043-51.
6. Schatzl G, Marberger M, Remzi M, et al. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer. Urology. 2005;65:1141-5.
7. Thompson I, Leach RJ, Pollock BH, Naylor SL. Prostate cancer and prostate-specific antigen: the more we know, the less we understand. J Natl Cancer Inst. 2003;95:1027-8.
8. Rao A, Cramer SD. Identification of a polymorphism in the ARE 1 region of the PSA promotor. Proc Am Assoc Cancer Res. 1999;40:65.
9. Xue WM, Coetzee GA, Ross RK, et al. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2001;10:575-9.
10. Medeiros R, Morais A, Vasconcelos A, et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate. 2002;53:88-94.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
12. International Union Against Cancer. Urological tumours: prostate. In: Hermanek P, Sobin LH, eds. TNM Classification of Malignant Tumors. 4 ed. Berlin: Springer-Verlag; 1992:141-4.
13. Bharaj B, Scorilas A, Diamandis EP, et al. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Res Treat. 2000;61:111-9.
14. Chiang CH, Chen KK, Chang LS, Hong CJ. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol. 2004;171:1529-32.
15. Severi G, Hayes VM, Neufing P, et al. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev. 2006;15:1142-7.
16. Jesser C, Mucci L, Farmer D, et al. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer. 2008;99:1743-7.
17. Kalay E, Ergen A, Narter F, et al. ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population. Anticancer Res. 2009;29:1395-8.
18. Wang LZ, Sato K, Tsuchiya N, et al. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett. 2003;202:53-9.
19. Shibahara T, Onishi T, Franco OE, et al. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population. Anticancer Res. 2006;26:3365-71.
20. Rao A, Chang BL, Hawkins G, et al. Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology. 2003;61:864-9.
21. Penney KL, Schumacher FR, Kraft P, et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011;32:853-9.
22. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev. 2005;14:2173-7.
23. Gsur A, Preyer M, Haidinger G, et al. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis. 2002;23:1647-51.
24. Binnie MC, Alexander FE, Heald C, Habib FK. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate. 2005;63:309-15.
25. Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2007;28:1032-9.
26. Xu J, Isaacs SD, Sun J, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008;14:5819-24.
27. Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2451-7.
28. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res. 2000;60:839-41.
29. Gunes S, Bagci H, Sarikaya S, Bilen CY, Kara N. Prostatespecific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol. 2007;26:873-8.
30. Dos Santos RM, De Jesus CM, Filho JC, Trindade JC, De Camargo JL, Rainho CA. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol. 2008;27:1-7.
31. Salinas CA, Austin MA, Ostrander EO, Stanford JL. Polymorphisms in the androgen receptor and the prostatespecific antigen genes and prostate cancer risk. Prostate. 2005;65:58-65.
32. Mononen N, Seppala EH, Duggal P, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 2006;66:743-7.